全文获取类型
收费全文 | 71150篇 |
免费 | 5925篇 |
国内免费 | 3264篇 |
专业分类
耳鼻咽喉 | 196篇 |
儿科学 | 1327篇 |
妇产科学 | 829篇 |
基础医学 | 12687篇 |
口腔科学 | 739篇 |
临床医学 | 5536篇 |
内科学 | 16731篇 |
皮肤病学 | 1072篇 |
神经病学 | 2647篇 |
特种医学 | 1293篇 |
外国民族医学 | 9篇 |
外科学 | 3876篇 |
综合类 | 10538篇 |
现状与发展 | 19篇 |
预防医学 | 6008篇 |
眼科学 | 485篇 |
药学 | 8831篇 |
18篇 | |
中国医学 | 3534篇 |
肿瘤学 | 3964篇 |
出版年
2023年 | 794篇 |
2022年 | 1851篇 |
2021年 | 2285篇 |
2020年 | 2147篇 |
2019年 | 2382篇 |
2018年 | 2273篇 |
2017年 | 2238篇 |
2016年 | 2602篇 |
2015年 | 2863篇 |
2014年 | 4651篇 |
2013年 | 4845篇 |
2012年 | 4777篇 |
2011年 | 5089篇 |
2010年 | 4120篇 |
2009年 | 3921篇 |
2008年 | 3873篇 |
2007年 | 3760篇 |
2006年 | 3427篇 |
2005年 | 2927篇 |
2004年 | 2424篇 |
2003年 | 2102篇 |
2002年 | 1710篇 |
2001年 | 1497篇 |
2000年 | 1155篇 |
1999年 | 1009篇 |
1998年 | 925篇 |
1997年 | 767篇 |
1996年 | 648篇 |
1995年 | 661篇 |
1994年 | 565篇 |
1993年 | 462篇 |
1992年 | 440篇 |
1991年 | 349篇 |
1990年 | 318篇 |
1989年 | 285篇 |
1988年 | 238篇 |
1987年 | 205篇 |
1986年 | 170篇 |
1985年 | 443篇 |
1984年 | 460篇 |
1983年 | 371篇 |
1982年 | 379篇 |
1981年 | 316篇 |
1980年 | 292篇 |
1979年 | 261篇 |
1978年 | 205篇 |
1977年 | 159篇 |
1976年 | 176篇 |
1975年 | 153篇 |
1974年 | 126篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
12.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
13.
This study aimed to observe the therapeutic effects of magnesium lithospermate B on acute and chronic colitis induced by dextran sodiumsulfate (DSS) and the role of inflammasome complex (NOD-like receptor protein, NLRP; apoptosis-associated speck-like protein containing, ASC; caspase-1). Establishment of acute and chronic colitis models were by using 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (240 mg/kg body weight) was given by subcutaneous injection. Samples were collected for biomarker assay, histological examination, immunohistochemical evaluation and western blot. There was obvious increase in TNF-α level and NLPR3, ASC, and caspase-1 expressions in acute and chronic colitis groups compared with the normal control. Significant decrease of the tumor necrosis factor-α level and the expressions of NLPR3, ASC, and caspase-1 were observed after treatment with magnesium lithospermate B. This study showed that magnesium lithospermate B could be used to treat acute and chronic colitis by inhibiting the activation of the NLRP3/ASC/Caspase-1 pathway. 相似文献
14.
Flavia Temperilli Aldona Rina Isabella Massimi Anna Lisa Montemari Maria Luisa Guarino Alessandra Zicari 《Platelets》2015,26(8):783-787
Serum thromboxane-B2 (TxB2), together with arachidonic acid (AA)-induced platelet aggregation, are, at the moment, the most used tests to identify patients displaying high on-aspirin treatment platelet reactivity (HAPR). Both tests are specific for aspirin action on cyclooxygenase-1. While the correlation between serum TxB2 assay and clinical outcome is established, data are conflicting with regard to aspirin treatment and a possible association with AA-stimulated platelet markers and clinical outcome. To understand such discrepancy, we performed a retrospective study to compare both assays. We collected data from 132 patients receiving a daily dose of aspirin (100?mg/day) and data from 48 patients receiving aspirin on alternate days. All Patients who received a daily dose of aspirin were studied for AA-induced platelet aggregation together with serum TxB2 levels and AA-induced TxB2 formation was also studied in 71 patients out of entire population. Consistent with recommendations in the literature, we defined HAPR by setting a cut-off point at 3.1?ng/ml for serum levels of thromboxane B2 and 20% for AA-induced platelet aggregation. According to this cut-off point, we divided our overall population into two groups: (1) TxB2?<?3.1?ng/ml and (2) TxB2?>?3.1?ng/ml. We found low agreement between such tests to identify patients displaying HAPR. Our results show that AA-induced platelet aggregation >20% identify a smaller number of HAPR patients in comparison with TxB2. A good correlation between serum TxB2 and arachidonic acid-induced TxB2 production was found (r?=?0.76619). 相似文献
15.
16.
目的 分析CSTB、A-FABP在膀胱癌诊断和预后的意义。方法 选取2014年1月至2016年7月在本院进行手术、病理证实的膀胱癌患者45例、良性膀胱病变患者88例,检测膀胱癌样本癌组织、癌旁组织、良性膀胱病变组织中CSTB、A-FABP表达水平。评价CSTB、A-FABP在鉴别诊断膀胱癌的效用。对比膀胱癌进展对象(2年内转移、复发、肿瘤死亡)以及未进展对象组织中CSTB、A-FABP表达水平。结果 癌组织、癌旁组织、良性病变对象组织中CSTB、A-FABP表达水平差异有统计学意义(P<0.05)。CSTB、A-FABP作为诊断标准(任意一项为阳性),鉴别诊断膀胱癌与良性病变的灵敏度为84.4%、特异度为90.9%、阳性预测值82.6%、阴性预测值92.0%、符合率88.7%。2年内转移、复发、肿瘤死亡的患者共30例,无转移、复发、死亡的患者共15例,膀胱癌进展对象CSTB、A FABP表达量高于未进展对象,差异有统计学意义(P<0.05)。结论 CSTB、A-FABP在膀胱癌诊断、预后预测中均有一定的临床价值。 相似文献
17.
18.
目的:分析延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响。方法:研究选取2017年1月~2017年12月某院肝二病区收治的112例乙型肝炎患者和2018年1月~2018年12月收治的98例乙型肝炎病毒患者作为研究对象,所有患者均进行抗病毒治疗,回顾性分析患者的病历资料。将2017年收治的112例患者作为常规组实施常规护理,将2018年收治的98例患者的作为研究组实施延续性护理,比较两组的护理效果。结果:研究组的治疗依从率为93.88%(92例),远高于常规组的77.68%(87例),两组数据比较存在统计学意义(P<0.05)。结论:延续性护理措施可以有效提高慢性乙型肝炎抗病毒治疗的依从性,可以在临床中推广使用。 相似文献
19.
20.
《中国现代医生》2020,58(2):135-138+封三
目的探讨实时剪切波弹性成像在评估拉米夫定治疗乙肝纤维化临床疗效中的作用。方法选取2017年1月~2018年1月我院收治的80例乙肝纤维化患者,根据随机数字法分为对照组和观察组,每组40例。对照组采用常规治疗,观察组在对照组的基础上给予拉米夫定进行治疗,治疗6个月。比较两组治疗前后肝功能、肝纤维化指标,利用实时剪切波弹性成像评估两组治疗前后肝脏弹性模量值及肝穿刺活检情况,并进行比较。结果两组治疗后AST、ALT、TBIL水平均明显低于治疗前,差异有统计学意义(P0.05);观察组治疗后AST、ALT、TBIL水平均明显低于对照组,差异有统计学意义(P0.05);两组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于治疗前,差异有统计学意义(P0.05);观察组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于对照组,差异有统计学意义(P0.05);与治疗前相比,两组治疗后肝穿刺活检结果均有好转,尤其是汇管区、肝小叶内炎症及肝纤维化改善明显。结论实时剪切波弹性成像作为肝脏硬度定量检测的无创性技术,可用于拉米夫定治疗乙肝纤维化临床疗效评估的重要方法。 相似文献